These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 28337527)

  • 1. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
    Baljevic M; Zaman S; Baladandayuthapani V; Lin YH; de Partovi CM; Berkova Z; Amini B; Thomas SK; Shah JJ; Weber DM; Fu M; Cleeland CS; Wang XS; Stellrecht CM; Davis RE; Gandhi V; Orlowski RZ
    Ann Hematol; 2017 Jun; 96(6):977-985. PubMed ID: 28337527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
    Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
    Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.
    Tolaney SM; Tan S; Guo H; Barry W; Van Allen E; Wagle N; Brock J; Larrabee K; Paweletz C; Ivanova E; Janne P; Overmoyer B; Wright JJ; Shapiro GI; Winer EP; Krop IE
    Invest New Drugs; 2015 Oct; 33(5):1108-14. PubMed ID: 26123926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
    Feldman DR; Einhorn LH; Quinn DI; Loriot Y; Joffe JK; Vaughn DJ; Fléchon A; Hajdenberg J; Halim AB; Zahir H; Motzer RJ
    Invest New Drugs; 2013 Aug; 31(4):1016-22. PubMed ID: 23417696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
    Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
    Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
    Kang YK; Muro K; Ryu MH; Yasui H; Nishina T; Ryoo BY; Kamiya Y; Akinaga S; Boku N
    Invest New Drugs; 2014 Apr; 32(2):355-61. PubMed ID: 24337769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.
    Yap TA; Olmos D; Brunetto AT; Tunariu N; Barriuso J; Riisnaes R; Pope L; Clark J; Futreal A; Germuska M; Collins D; deSouza NM; Leach MO; Savage RE; Waghorne C; Chai F; Garmey E; Schwartz B; Kaye SB; de Bono JS
    J Clin Oncol; 2011 Apr; 29(10):1271-9. PubMed ID: 21383285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
    Front Immunol; 2021; 12():731527. PubMed ID: 34804015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
    Geller JI; Perentesis JP; Liu X; Minard CG; Kudgus RA; Reid JM; Fox E; Blaney SM; Weigel BJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28449393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
    Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
    Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
    Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
    Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
    Wagner AJ; Goldberg JM; Dubois SG; Choy E; Rosen L; Pappo A; Geller J; Judson I; Hogg D; Senzer N; Davis IJ; Chai F; Waghorne C; Schwartz B; Demetri GD
    Cancer; 2012 Dec; 118(23):5894-902. PubMed ID: 22605650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
    Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
    Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
    Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
    Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
    Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
    Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
    Pant S; Saleh M; Bendell J; Infante JR; Jones S; Kurkjian CD; Moore KM; Kazakin J; Abbadessa G; Wang Y; Chen Y; Schwartz B; Camacho LH
    Ann Oncol; 2014 Jul; 25(7):1416-1421. PubMed ID: 24737778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.
    Santoro A; Simonelli M; Rodriguez-Lope C; Zucali P; Camacho LH; Granito A; Senzer N; Rimassa L; Abbadessa G; Schwartz B; Lamar M; Savage RE; Bruix J
    Br J Cancer; 2013 Jan; 108(1):21-4. PubMed ID: 23287988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.
    Lath DL; Buckle CH; Evans HR; Fisher M; Down JM; Lawson MA; Chantry AD
    PLoS One; 2018; 13(6):e0199517. PubMed ID: 29924867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.